Is Thymosin Alpha-1 Legal in Virginia?

HealthRX.com

Thymosin alpha-1 is not FDA-approved or allowed for compounding

Print or save as PDF

Key numbers

  • 1.6 mgStrength of the finished Zadaxin injection sold outside the US, not interchangeable with bulk powderSource: fda.gov, as cited Nov 7, 2026
  • 17 noAdvisory committee votes against adding thymosin alpha-1 to the pharmacy bulks listSource: fda.gov, as cited Nov 7, 2026
  • category 3FDA outsourcing facilities list places thymosin alpha-1 in category 3, nominated without adequate supportSource: fda.gov, as cited Nov 7, 2026
  • FDA approval / Not approved; four orphan drug designations are not approvals [1]
  • Foreign approvals / Approved as a medicine in some other countries; FDA lists Italy, India and Hong Kong [1]
  • Pharmacy bulks list / FDA proposed not adding it; advisory committee voted 17 no, 4 yes [3]
  • State-licensed pharmacy categories / In none of the three categories [2]
  • Outsourcing facilities / Category 3, nominated without adequate support [5]
  • HHS peptide policy / Not one of the six peptides in the October 2026 draft [4]

What is thymosin alpha-1?

Thymosin alpha-1 is a 28-amino-acid peptide; thymalfasin is the synthetic version with the same sequence, and Zadaxin is the finished 1.6 mg injection sold outside the United States, not interchangeable with bulk thymosin alpha-1 powder [1]. A Drugs@FDA search found no US application, so it is not approved in the United States [1]. It has four US orphan drug designations, but orphan designation is not approval [1]. FDA lists authorizations in other countries, including Italy, India and Hong Kong; these are separate from any US approval [1].

Has FDA allowed compounding?

FDA proposed that thymosin alpha-1 not be added to the pharmacy bulks list. On December 4, 2024, the Pharmacy Compounding Advisory Committee voted 4 yes and 17 no, with no abstentions, on both the free base and the acetate; members who voted no cited no compelling evidence of clinical effectiveness and safety [3].

On FDA's list for state-licensed pharmacies and physicians, thymosin alpha-1 is in none of the three categories [2]. On FDA's list for outsourcing facilities, it is in category 3, 'nominated without adequate support' [5]. FDA's category 1 policy, which generally says no action against compounders if conditions are met, does not apply to it [2].

FDA's safety-risk page lists thymosin alpha-1 in the 'nominated but withdrawn' table: it had been in category 2 for significant safety risks and came off after the nominators withdrew. FDA's concerns remain posted, including significant risk for immunogenicity for certain routes of administration, peptide-impurity and characterization problems, and safety information inadequate for the agency to understand the extent of any safety issues [6].

Thymosin alpha-1 is not one of the six peptides in HHS's October 2026 draft enforcement-discretion policy (BPC-157, epitalon, KPV, MOTS-c, Semax and TB-500) [4].

Does Virginia law change the answer?

The federal findings above do not show whether Virginia permits or prohibits thymosin alpha-1. What is documented is the federal position that applies to Virginia as to every state: no FDA approval, a proposed exclusion from the pharmacy bulks list, and no identified FDA or HHS action allowing compounding [1][2][3][4].

Check what you know

Think you have it? Try 3 quick questions and see what the article says.

1. According to the article, what does orphan drug designation mean for thymosin alpha-1?

Question 1 of 3

Score: 0 right, 0 of 3 answered

Questions worth asking

Choose the questions you want to keep

Is thymosin alpha-1 legal in Virginia?
Federal findings alone do not settle it. Thymosin alpha-1 is not FDA-approved, and FDA proposed not adding it to the pharmacy bulks list [1][3].
Is thymosin alpha-1 FDA-approved?
No. A Drugs@FDA search found no US application, and its four orphan drug designations are not approvals [1].
Has FDA allowed thymosin alpha-1 compounding?
No FDA or HHS action allowing it was identified. FDA's category 1 policy for state-licensed pharmacies does not apply to it [2][3][4].
Does the October 2026 HHS peptide policy cover thymosin alpha-1?
No. The draft covers BPC-157, epitalon, KPV, MOTS-c, Semax and TB-500, not thymosin alpha-1 [4].

Reader questions

What people actually ask

Short answers drawn from the sources this article cites.

Is thymosin alpha 1 legal?

Federal findings alone do not settle it. Thymosin alpha-1 is not FDA-approved and has no federal compounding allowance, and FDA proposed not adding it to the pharmacy bulks list. Federal findings do not show whether Virginia permits or prohibits it.

Is TB 500 the same as thymosin alpha 1?

They are not established as the same. Thymosin alpha-1 is not one of the six peptides in HHS's October 2026 draft enforcement-discretion policy, which lists TB-500 as one of them.

Is thymosin alpha 1 safe?

Safety is not established. FDA's safety-risk page lists thymosin alpha-1 as nominated but withdrawn, after it had been in category 2 for significant safety risks. FDA's posted concerns include significant risk for immunogenicity for certain routes of administration, peptide-impurity and characterization problems, and safety information inadequate for the agency to understand the extent of any safety issues.

Show all 6 referencesHide references
Evidence overview for Is Thymosin Alpha-1 Legal in Virginia?